Table 2.

Comparison of characteristics of patients with SLE with or without fatigue

Characteristics	Patients with fatigue (n=257)	Patients without fatigue (n=93)	P value
Age, years, median (IQR 25–75)	43 (35–54), n=257	41 (31–47), n=93	0.03
Sex (female)	230 (89), n=257	82 (88), n=93	0.70
Anxiety	97 (42), n=232	9 (11), n=84	<0.0001
Depression	34 (15), n=224	2 (2), n=80	0.002
PGA, median (IQR 25–75)	0.5 (0.2–1), n=257	0.3 (0.2–0.95), n=93	0.004
SELENA-SLEDAI, median (IQR 25–75)	4 (1.5–6), n=257	2 (2–5), n=93	0.43
Hydroxychloroquine	198 (79), n=249	74 (81), n=91	0.76
Any GC	173 (67), n=257	52 (56), n=93	0.06
GC >10 mg/day	50 (20), n=250	15 (17), n=89	0.64
Any IS	114 (44), n=257	37 (40), n=93	0.46

P values in bold indicate significance.

All results are presented as n (%) unless stated otherwise.

‘n=’ means number of patients with available data.

IS agents include azathioprine or methotrexate or mycophenolate or cyclophosphamide or rituximab or belimumab.

GC, glucocorticoids; IQR 25–75, 25th–75th percentile IQR; IS, immunosuppressive agent; PGA, Physician Global Assessment; SELENA, Safety of Estrogens in Lupus Erythematosus National Assessment; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.